Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2640–2645. doi: 10.1128/aac.41.12.2640

Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.

I Tegeder 1, F Bremer 1, R Oelkers 1, H Schobel 1, J Schüttler 1, K Brune 1, G Geisslinger 1
PMCID: PMC164183  PMID: 9420033

Abstract

The pharmacokinetics of imipenem-cilastatin were investigated in 12 critically ill patients with acute renal failure (ARF) managed by continuous veno-venous hemofiltration (CVVH) while receiving a fixed combination of 500 mg of imipenem-cilastatin intravenously three or four times daily. No adverse drug reactions were observed. Plasma and hemofiltrate samples were taken at specified times during one dosing interval, and the concentrations of imipenem and cilastatin were determined by high-performance liquid chromatography. Pharmacokinetic variables were calculated by a first-order, two-compartment pharmacokinetic model for both substances. Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively. Mean imipenem dosage requirements were approximately 2,000 mg/24 h (2,111.8 +/- 493.4 mg/24 h). They were calculated in order to achieve an average steady-state concentration of 12 mg/liter to ensure that concentrations in plasma exceeded the MICs at which 90% of intermediately resistent bacteria are inhibited (8 mg/liter) during the majority of the dosing interval. By contrast, the recommended dosage for patients with end-stage renal failure (ESRF) and infections caused by intermediately resistant bacteria is 1,000 mg/24 h. This remarkable difference may be due (i) to differences in the nonrenal clearance of imipenem between patients with ARF and ESRF and (ii) to the additional clearance by the hemofilter. Since the total clearance of cilastatin was low, marked accumulation occurred, and this was particularly pronounced in patients with additional liver dysfunction. Thus, in patients with ARF managed by CVVH, rather high imipenem doses are required, and these inevitably result in a marked accumulation of cilastatin. The doses of imipenem recommended for patients with ESRF, however, will lead to underdosing and inadequate antibiotic therapy.

Full Text

The Full Text of this article is available as a PDF (158.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarabi A. A., Cars O., Danielson B. G., Salmonson T., Wikström B. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. J Antimicrob Chemother. 1990 Jul;26(1):91–98. doi: 10.1093/jac/26.1.91. [DOI] [PubMed] [Google Scholar]
  2. Bennett W. M. Guide to drug dosage in renal failure. Clin Pharmacokinet. 1988 Nov;15(5):326–354. doi: 10.2165/00003088-198815050-00005. [DOI] [PubMed] [Google Scholar]
  3. Berman S. J., Sugihara J. G., Nakamura J. M., Kawahara K. K., Wong E. G., Musgrave J. E., Wong L. M., Siemsen A. M. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. Am J Med. 1985 Jun 7;78(6A):113–116. doi: 10.1016/0002-9343(85)90112-3. [DOI] [PubMed] [Google Scholar]
  4. Bickley S. K. Drug dosing during continuous arteriovenous hemofiltration. Clin Pharm. 1988 Mar;7(3):198–206. [PubMed] [Google Scholar]
  5. Birnbaum J., Kahan F. M., Kropp H., MacDonald J. S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med. 1985 Jun 7;78(6A):3–21. doi: 10.1016/0002-9343(85)90097-x. [DOI] [PubMed] [Google Scholar]
  6. Braveny I. In vitro activity of imipenem--a review. Eur J Clin Microbiol. 1984 Oct;3(5):456–462. doi: 10.1007/BF02017375. [DOI] [PubMed] [Google Scholar]
  7. Calandra G. B., Brown K. R., Grad L. C., Ahonkhai V. I., Wang C., Aziz M. A. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med. 1985 Jun 7;78(6A):73–78. doi: 10.1016/0002-9343(85)90104-4. [DOI] [PubMed] [Google Scholar]
  8. Drusano G. L., Standiford H. C. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med. 1985 Jun 7;78(6A):47–53. doi: 10.1016/0002-9343(85)90101-9. [DOI] [PubMed] [Google Scholar]
  9. Finch R. G., Craddock C., Kelly J., Deaney N. B. Pharmacokinetic studies of imipenem/cilastatin in elderly patients. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):103–107. doi: 10.1093/jac/18.supplement_e.103. [DOI] [PubMed] [Google Scholar]
  10. Gibson T. P., Demetriades J. L., Bland J. A. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med. 1985 Jun 7;78(6A):54–61. doi: 10.1016/0002-9343(85)90102-0. [DOI] [PubMed] [Google Scholar]
  11. Gibson T. P. Renal disease and drug metabolism: an overview. Am J Kidney Dis. 1986 Jul;8(1):7–17. doi: 10.1016/s0272-6386(86)80148-2. [DOI] [PubMed] [Google Scholar]
  12. Golper T. A., Pulliam J., Bennett W. M. Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med. 1985 Sep;145(9):1651–1652. [PubMed] [Google Scholar]
  13. Gravallese D. A., Musson D. G., Pauliukonis L. T., Bayne W. F. Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability. J Chromatogr. 1984 Sep 14;310(1):71–84. doi: 10.1016/0378-4347(84)80069-9. [DOI] [PubMed] [Google Scholar]
  14. Hyatt J. M., McKinnon P. S., Zimmer G. S., Schentag J. J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995 Feb;28(2):143–160. doi: 10.2165/00003088-199528020-00005. [DOI] [PubMed] [Google Scholar]
  15. Imbimbo B. P., Imbimbo E., Daniotti S., Verotta D., Bassotti G. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci. 1988 Sep;77(9):784–789. doi: 10.1002/jps.2600770914. [DOI] [PubMed] [Google Scholar]
  16. Jelliffe R. W., Jelliffe S. M. Estimation of creatinine clearance from changing serum-creatinine levels. Lancet. 1971 Sep 25;2(7726):710–710. doi: 10.1016/s0140-6736(71)92283-5. [DOI] [PubMed] [Google Scholar]
  17. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  18. Keller E., Fecht H., Böhler J., Schollmeyer P. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant. 1989;4(7):640–645. [PubMed] [Google Scholar]
  19. Konishi K., Suzuki H., Saruta T., Hayashi M., Deguchi N., Tazaki H., Hisaka A. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimicrob Agents Chemother. 1991 Aug;35(8):1616–1620. doi: 10.1128/aac.35.8.1616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Majcherczyk P. A., Kunz S., Hattenberger M., Vaxelaire J., Zak O., O'Reilly T. Isolation and in-vitro and in-vivo characterisation of a mutant of Pseudomonas aeruginosa PAO1 that exhibited a reduced postantibiotic effect in response to imipenem. J Antimicrob Chemother. 1994 Oct;34(4):485–505. doi: 10.1093/jac/34.4.485. [DOI] [PubMed] [Google Scholar]
  21. Mueller B. A., Scarim S. K., Macias W. L. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993 Feb;21(2):172–179. doi: 10.1016/s0272-6386(12)81089-4. [DOI] [PubMed] [Google Scholar]
  22. Myers C. M., Blumer J. L. Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1984 Jul;26(1):78–81. doi: 10.1128/aac.26.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Norrby S. R., Alestig K., Björnegård B., Burman L. A., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Kahan J. S., Kropp H. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983 Feb;23(2):300–307. doi: 10.1128/aac.23.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Norrby S. R., Rogers J. D., Ferber F., Jones K. H., Zacchei A. G., Weidner L. L., Demetriades J. L., Gravallese D. A., Hsieh J. Y. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):707–714. doi: 10.1128/aac.26.5.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Przechera M., Bengel D., Risler T. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration. Contrib Nephrol. 1991;93:131–134. doi: 10.1159/000420202. [DOI] [PubMed] [Google Scholar]
  26. Reetze-Bonorden P., Böhler J., Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993 May;24(5):362–379. doi: 10.2165/00003088-199324050-00002. [DOI] [PubMed] [Google Scholar]
  27. Smith G. B., Dezeny G. C., Douglas A. W. Stability and kinetics of degradation of imipenem in aqueous solution. J Pharm Sci. 1990 Aug;79(8):732–740. doi: 10.1002/jps.2600790816. [DOI] [PubMed] [Google Scholar]
  28. Somani P., Freimer E. H., Gross M. L., Higgins J. T., Jr Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1988 Apr;32(4):530–534. doi: 10.1128/aac.32.4.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. St Peter W. L., Redic-Kill K. A., Halstenson C. E. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet. 1992 Mar;22(3):169–210. doi: 10.2165/00003088-199222030-00002. [DOI] [PubMed] [Google Scholar]
  30. Storck M., Hartl W. H., Zimmerer E., Inthorn D. Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure. Lancet. 1991 Feb 23;337(8739):452–455. doi: 10.1016/0140-6736(91)93393-n. [DOI] [PubMed] [Google Scholar]
  31. Verpooten G. A., Verbist L., Buntinx A. P., Entwistle L. A., Jones K. H., De Broe M. E. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol. 1984 Aug;18(2):183–193. doi: 10.1111/j.1365-2125.1984.tb02451.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vesconi S., Sicignano A., De Pietri P., Foroni C., Minuto A., Bellato V., Riboni A. Continuous veno-venous hemofiltration in critically ill patients with multiple organ failure. Int J Artif Organs. 1993 Aug;16(8):592–598. [PubMed] [Google Scholar]
  33. Vos M. C., Vincent H. H., Yzerman E. P. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med. 1992;18(5):282–285. doi: 10.1007/BF01706474. [DOI] [PubMed] [Google Scholar]
  34. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES